JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v8i5.7053ArticleTreatment Efficacy and Safety of Bortezomib Combined with Dexamethasone and Lenalidomide Chemotherapy Regimen for Multiple Myeloma https://artdesignp.com/journal/JCNR/8/5/10.26689/jcnr.v8i5.7053YuanChangyong,CuiNa,LiuShumei2024852024-06-14Objective: To analyze the effect of bortezomib combined with dexamethasone and lenalidomide in the treatment of multiple myeloma. Methods: 60 cases of multiple myeloma patients admitted to our hospital from January 2022 to December 2023 were selected randomly, with 30 cases in each group. Bortezomib combined with dexamethasone was administered in the control group, and bortezomib combined with dexamethasone and lenalidomide was given to the observation group, and the treatment effect was analyzed. Results: After treatment, CD3+ and CD4+ of the observation group were higher than that of the control group, CD8+ was lower than that of the control group, and the total treatment efficiency was higher, which was statistically significant (P < 0.05), and there was no difference in the total incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Bortezomib combined with dexamethasone and lenalidomide is effective in the treatment of multiple myeloma as it regulates the immune function and is safe, thus it can be promoted in clinical practice.

Mao P, Yang C, 2023, Efficacy and Safety Evaluation of Bortezomib Combined with Dexamethasone and Lenalidomide Chemotherapy in the Treatment of Multiple Myeloma. Journal of Practical Cancer, 2023(3): 502–506.

Xu H, Wang M, Jiang X, et al., 2022, Efficacy and Safety of Bortezomib Combined with Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma. Journal of Clinical Hematology, 35(1): 46–51.

Lin HL, 2023, Efficacy of Lenalidomide Combined with Bortezomib and Dexamethasone in the Treatment of Multiple Myeloma and Its Effect on MMP-13 and NF-?Bp65. Journal of Clinical Rational Drug Use, 16(27): 111–114.

Vaxman I, Visram A, Kapoor P, et al., 2020, Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation, 136(11): 21–22.

Wang Y, 2021, Efficacy of Bortezomib, Dexamethasone and Lenalidomide in the Treatment of Multiple Myeloma. Contemporary Medicine, 19(20): 109–111.

Wang G, 2021, Analysis of the Effective Value of Applying Lenalidomide Combined with Low-Dose Dexamethasone in the Treatment of Relapsed Refractory Multiple Myeloma. Northern Pharmacology, 2021(6): 125–126.

Zhang Y, Zhou M, 2022, Clinical Efficacy of Bortezomib Combined with Lenalidomide and Dexamethasone (VRD) Regimen and Bortezomib Combined with Thalidomide and Dexamethasone (VTD) Regimen in the Treatment of Multiple Myeloma. Systems Medicine, 7(1): 102–105.

Lazana I, Floro L, Christmas T, et al., 2022, Autologous Stem Cell Transplantation for Multiple Myeloma Patients with Chronic Kidney Disease: A Safe and Effective Option. Bone Marrow Transplantation, 2022(57): 959–965.

Huang D, Zhu YY, Xiao Y, et al., 2022, Cost-Utility Analysis of Dexamethasone Combined with Bortezomib and Lenalidomide for the Treatment of Newly Diagnosed Multiple Myeloma. China Pharmacy, 33(16): 2001–2005.

Zhou Q, Xu F, Wen J, et al., 2023, Evaluation of the Efficacy of Sequential Lenalidomide Continuous Therapy with Bortezomib-Based Initial Chemotherapy in Untransplanted Primary Multiple Myeloma. West Med, 35(9): 1304–1309.

Kuypers J, Simmance N, Quach H, et al., 2022, Nutrition Support Use and Clinical Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. Supportive Care in Cancer, 30(11): 9341–9350.

Tao J, Zhu XJ, Liu YB, 2022, Effect of Bortezomib-Containing PAD, PCD, VRD Regimen in the Treatment of Primary Multiple Myeloma and Its Impact on Cellular Immunity Indexes and Safety. Clinical Misdiagnosis and Mistreatment, 35(5): 35–38.

Chen L, 2021, Efficacy of Lenalidomide Combined with Bortezomib in the Treatment of Multiple Myeloma and Its Effect on the Content of Immune-Related Cytokines. Medicine and Health Care, 29(4): 53–54.

Cai Y, Ding L, Chen T, et al., 2023, Study on the Safety of Bortezomib Combined with Dexamethasone and Lenalidomide Chemotherapy in the Treatment of Multiple Myeloma. Systemic Medicine, 8(14): 44–47.

Martino M, Pitino A, Tripepi G, et al., 2021, The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation. Clinical Lymphoma Myeloma and Leukemia, 21(4): e402–e409.